Tuo-Yen Tseng1, Jamie S Ostroff2, Alena Campo1, Meghan Gerard1, Thomas Kirchner1,3, John Rotrosen4, Donna Shelley1. 1. Department of Population Health, New York University School of Medicine, New York, NY. 2. Behavioral Sciences Service, Memorial Sloan Kettering Cancer Center, New York, NY. 3. New York University College of Global Public Health, New York, NY. 4. Department of Psychiatry, New York University School of Medicine, New York, NY.
Abstract
INTRODUCTION:Electronic cigarette (EC) use is growing dramatically with use highest among young adults and current smokers. One of the most common reasons for using ECs is interest in quitting or reducing cigarettes per day (CPD); however there are few randomized controlled trials (RCT) on the effect of ECs on smoking abstinence and reduction. METHODS: We conducted a two-arm; double-blind RCT. Subjects were randomized to receive 3-weeks of either disposable 4.5% nicotine EC (intervention) or placebo EC. The primary outcome was self-reported reduction of at least 50% in the number of CPDs smoked at week 3 (end of treatment) compared to baseline. Study subjects (n = 99) were young adult (21-35), current smokers (smoked ≥ 10 CPDs) living in NYC. RESULTS: Compared with baseline, a significant reduction in CPDs was observed at both study time periods (1 and 3 weeks) for intervention (P < .001) and placebo (P < .001) groups. Between-group analyses showed significantly fewer CPDs in the intervention group compared to the placebo group at week 3 (P = .03), but not at any other follow-up periods. The logistic regression analysis showed that using a greater number of ECs, treatment condition and higher baseline readiness to quit were significantly associated with achieving at least 50% reduction in CPDs at the end of treatment. CONCLUSION:A diverse young adult sample of current everyday smokers, who were not ready to quit, was able to reduce smoking with the help of ECs. Further study is needed to establish the role of both placebo and nicotine containing ECs in increasing both reduction and subsequent cessation. IMPLICATIONS: Despite the critical need for well-designed clinical trials on the effect of ECs on cessation and cigarette reduction, the majority of studies have been observational or noncomparative intervention designs. Only three RCTs studying ECs as a cessation or reduction intervention have been published, and none were conducted in the United States. The current study adds knowledge to current literature on the feasibility of using ECs to aid smoking reduction among young smokers in US urban populations.
RCT Entities:
INTRODUCTION: Electronic cigarette (EC) use is growing dramatically with use highest among young adults and current smokers. One of the most common reasons for using ECs is interest in quitting or reducing cigarettes per day (CPD); however there are few randomized controlled trials (RCT) on the effect of ECs on smoking abstinence and reduction. METHODS: We conducted a two-arm; double-blind RCT. Subjects were randomized to receive 3-weeks of either disposable 4.5% nicotine EC (intervention) or placebo EC. The primary outcome was self-reported reduction of at least 50% in the number of CPDs smoked at week 3 (end of treatment) compared to baseline. Study subjects (n = 99) were young adult (21-35), current smokers (smoked ≥ 10 CPDs) living in NYC. RESULTS: Compared with baseline, a significant reduction in CPDs was observed at both study time periods (1 and 3 weeks) for intervention (P < .001) and placebo (P < .001) groups. Between-group analyses showed significantly fewer CPDs in the intervention group compared to the placebo group at week 3 (P = .03), but not at any other follow-up periods. The logistic regression analysis showed that using a greater number of ECs, treatment condition and higher baseline readiness to quit were significantly associated with achieving at least 50% reduction in CPDs at the end of treatment. CONCLUSION: A diverse young adult sample of current everyday smokers, who were not ready to quit, was able to reduce smoking with the help of ECs. Further study is needed to establish the role of both placebo and nicotine containing ECs in increasing both reduction and subsequent cessation. IMPLICATIONS: Despite the critical need for well-designed clinical trials on the effect of ECs on cessation and cigarette reduction, the majority of studies have been observational or noncomparative intervention designs. Only three RCTs studying ECs as a cessation or reduction intervention have been published, and none were conducted in the United States. The current study adds knowledge to current literature on the feasibility of using ECs to aid smoking reduction among young smokers in US urban populations.
Authors: Jed E Rose; Al Salley; Frederique M Behm; James E Bates; Eric C Westman Journal: Psychopharmacology (Berl) Date: 2010-04-01 Impact factor: 4.530
Authors: Sarah E Adkison; Richard J O'Connor; Maansi Bansal-Travers; Andrew Hyland; Ron Borland; Hua-Hie Yong; K Michael Cummings; Ann McNeill; James F Thrasher; David Hammond; Geoffrey T Fong Journal: Am J Prev Med Date: 2013-03 Impact factor: 5.043
Authors: Russell E Glasgow; Bridget Gaglio; Paul A Estabrooks; Alfred C Marcus; Debra P Ritzwoller; Tammy L Smith; Arnold H Levinson; Anna Sukhanova; Colin O'Donnell; Erica F Ferro; Eric K France Journal: Med Care Date: 2009-01 Impact factor: 2.983
Authors: Anne M Joseph; Stephen S Hecht; Sharon E Murphy; Harry Lando; Steven G Carmella; Myron Gross; Robin Bliss; Chap T Le; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2008-03 Impact factor: 4.244
Authors: David B Abrams; Allison M Glasser; Andrea C Villanti; Jennifer L Pearson; Shyanika Rose; Raymond S Niaura Journal: Prev Med Date: 2018-06-23 Impact factor: 4.018
Authors: Allison M Glasser; Mahathi Vojjala; Jennifer Cantrell; David T Levy; Daniel P Giovenco; David Abrams; Raymond Niaura Journal: Nicotine Tob Res Date: 2021-03-19 Impact factor: 4.244
Authors: Jenny E Ozga-Hess; Nicholas J Felicione; Stuart G Ferguson; Geri Dino; Daniel Elswick; Catherine Whitworth; Nicholas Turiano; Melissa D Blank Journal: Addict Behav Date: 2019-08-21 Impact factor: 3.913
Authors: Matthew J Carpenter; Bryan W Heckman; Amy E Wahlquist; Theodore L Wagener; Maciej L Goniewicz; Kevin M Gray; Brett Froeliger; K Michael Cummings Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-10 Impact factor: 4.254
Authors: Kim Pulvers; Ashley S Emami; Nicole L Nollen; Devan R Romero; David R Strong; Neal L Benowitz; Jasjit S Ahluwalia Journal: Nicotine Tob Res Date: 2018-01-05 Impact factor: 4.244
Authors: Karen O Brandon; Vani N Simmons; Lauren R Meltzer; David J Drobes; Úrsula Martínez; Steven K Sutton; Amanda M Palmer; Christopher R Bullen; Paul T Harrell; Thomas H Brandon Journal: Addiction Date: 2019-02-13 Impact factor: 6.526